The epigenetic feedback loop between DNA methylation and microRNAs in fibrotic disease with an emphasis on DNA methyltransferases  by Sun, Xu et al.
Cellular Signalling 25 (2013) 1870–1876
Contents lists available at SciVerse ScienceDirect
Cellular Signalling
j ourna l homepage: www.e lsev ie r .com/ locate /ce l l s igReviewThe epigenetic feedback loop between DNA methylation and
microRNAs in ﬁbrotic disease with an emphasis on
DNA methyltransferasesXu Sun, Yong He, Cheng Huang, Tao-Tao Ma, Jun Li ⁎
School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, China
Institute for Liver Diseases of Anhui Medical University (AMU), Hefei 230032, ChinaAbbreviations: miRNA, microRNA; DNMTs, DNA me
SOCS1, cytokine signaling-1 gene; PPARγ, peroxisome p
Spp1, secreted phosphoprotein 1; HCV, chronic hepatiti
⁎ Corresponding author at: School of Pharmacy, Anhu
E-mail addresses: lj@ahmu.edu.cn, sunxuapril@hotm
0898-6568 © 2013 The Authors. Published by Elsevier I
http://dx.doi.org/10.1016/j.cellsig.2013.05.013a b s t r a c ta r t i c l e i n f oArticle history:
Received 29 April 2013
Accepted 7 May 2013
Available online 22 May 2013
Keywords:
MicroRNA
DNA methylation
DNMTs
Fibroblast
Myoﬁbroblast
FibrogenesisEpigenetic processes play a key regulatory role in many cancers. Recently, it also has been demonstrated to
participate in ﬁbrogenesis, especially in ﬁbrotic disease. Fibrotic disease is a pathological response to tissue
injury which can occur in any organ. Mechanisms that orchestrate ﬁbrotic disorders in different organs are
amazingly generic, involving generation of activated ﬁbroblasts and myoﬁbroblasts by differentiation pro-
cesses that require extensive alterations in gene expression. Apart from genetic and environmental factors,
epigenetic modiﬁcations including a combination of microRNAs and DNA methylation are supposed as reg-
ulatory mechanisms to control myoﬁbroblast differentiation. It has become obvious that microRNAs, which
act as regulators of gene expression at a post-transcriptional level, are differentially expressed in differen-
tiating cells and play important roles in governing DNAmethyltransferases (DNMTs) which are enzymes re-
sponsible for setting up and maintaining DNA methylation patterns at speciﬁc regions of the genome. Some
microRNAs targeting DNMT transcripts lead to the demethylation and transcriptional activation of numer-
ous protein coding gene sequences, thereby contributing to gene expression. Moreover, DNMTs also have a
critical role in controlling some speciﬁc microRNA expression. This cooperative action among DNMTs,
microRNAs andDNAmethylation indicates that DNMTsmay participate in the pathogenesis ofmyoﬁbroblast dif-
ferentiation through silencing of certain gene transcription. In this review,we summarize the current knowledge
of a potential link between microRNA expression and DNA methylation on how DNMTs work in the process of
ﬁbrogenesis.
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Fibrosis is the ﬁnal, common pathological outcome of many chron-
ic inﬂammatory diseases. It is estimated that one-third of naturally
occurring deaths worldwide are associated with ﬁbrosis diseases [1].
In general, ﬁbrosis is deﬁned by the excessive accumulation of ﬁbrous
connective tissue (components of the extracellular matrix (ECM)
such as collagen and ﬁbronectin) in and around inﬂamed or damaged
tissue, which can lead to permanent scarring, organ malfunction and,
ultimately, death, as seen in lung, liver, kidney, heart, bone marrow,
skin, intestine and scleroderma/systemic sclerosis [2]. Throughout
the past decade, there have been accumulating investigations undertak-
en which have demonstrated the molecular mechanisms underlying
ﬁbrosis. It is generally accepted that myoﬁbroblast is the major cellular
driver of ﬁbrosis inmost tissue. Myoﬁbroblasts are rare in normal tissue
but they are destined in response to inﬂammation by progression as
well as reversal of ﬁbrosis. Regulation of myoﬁbroblast differentiation
is primarily investigated in terms of the regulation of ﬁbroblast activa-
tion and myoﬁbroblast marker genes, especially the key marker of
differentiation, α-smooth muscle actin (α-SMA; gene ACTA). Although
the understanding of the mechanisms of myoﬁbroblast differentiation
is not fully clear, it is believed that it arises from interplay of epigenetic
modiﬁcations, genetic factors and environmental factors [3–5].
Epigenetics in general is the study of the variations of genetic
expression that occur not because of a change in DNA sequence, but
because of chromatin alternations that modulate DNA transcription.
The mechanisms of epigenetics are thus the link between genome and
phenotype. Epigenetic effects may particularly modify phenotype, and
persist throughout the whole life of cell divisions [6,7]. The epigenetic
processes and indeed phenotype of cells are orchestrated by the com-
bined inﬂuences of molecular components of epigenome including DNA
methylation and posttranslational modiﬁcations of regulatory noncoding
RNAs, especially, microRNAs (miRNAs) [8]. DNA methylation is an es-
sential epigenetic modiﬁcation on chromosomes that plays an impor-
tant role in the regulation of gene transcription. When the cytosine
and guanine contents are greater than 50% in the DNA sequence of
humans, the high CG content regions can be hypermethylated causing
transcriptional silencing [9,10]. MiRNAs, however, are endogenous
small (19–25 nt) non-coding RNAs that regulate gene expression by
speciﬁcally interacting with 3′ untranslated region (3′-UTR) of target
genemRNAs to repress translation or enhancemRNA cleavage [11]. De-
regulation of epigenetic processes for example, the silencing of tumor
suppressor proteins [12–14], is a common hallmark of cancer. As for ﬁ-
brotic disease, emerging evidences have demonstrated that epigenetic
processes played an important role in themechanisms ofmyoﬁbroblast
differentiation [8].
DNA methyltransferases (DNMTs), as the key enzymes to mediate
the transfer of a methyl group from S-adenosylmethionine (SAM) to cy-
tosine residues at CpG dinucleotides [15], have shown two methylation
activities: (1) maintenance of methylation of the symmetrical cytosine
at a double-stranded hemimethylated CpG, and (2) de novomethylation
of unmethylated CpG dinucleotides during DNA replication [16–18].
The former ensures the maintenance of the normal methylation status
of newly synthesized genomic DNA and the latter is associated with
changes in gene expression during differentiation and aging [19,20].
In mammals, ﬁve members of the DNMT protein family have been
discovered (DNMT-1, DNMT-2, DNMT-3a, DNMT-3b, and DNMT-3L), of
which only three are shown to possess catalytic methyltransferase activ-
ity (DNMT-1, DNMT-3a, and DNMT-3b). DNMT-1 is the most abundant
form in eukaryotic cells with higher priority to maintain DNA methyla-
tion in dividing cells, while DNMT-3a and DNMT-3b are responsible for
de novo methylation during embryonic development [21]. They are
concerned to play a role at speciﬁc regions of the genome, thereby con-
tributing to gene regulation. Many researches have focused on how
DNMTs in a ubiquitously expressed transcriptional repressor could result
in speciﬁc ﬁbrosis deﬁcits. This reviewwill discuss the DNAmethylationandmicroRNAmachinery inﬁbrotic disease, aswell as a potential impor-
tant role of DNMTs involved in mediating transcriptional repression in
the pathogenesis of ﬁbrogenesis.
2. An overview of myoﬁbroblast differentiation in ﬁbrotic disease
Myoﬁbroblasts, which are characterized in ﬁbrotic disease by
overexpression of α-smooth muscle actin (α-SMA; gene ACTA) and
other marker genes for their anatomic localization and degree of activa-
tion [4], appear de novo in response to tissue injury alongwith their abil-
ity to express high levels of extracellularmatrix and ﬁbrogenic cytokines
and apoptosis upon successful repair with gradual disappearance [3,5].
Regulation of myoﬁbroblast differentiation is primarily investigated
in terms of differentiation and activation of ﬁbroblasts. Mounting evi-
dence describes signal transduction molecules and transcription factor
in activated ﬁbroblasts as the key element to control the expression of
ﬁbrogenic characteristics of themyoﬁbroblasts such as contractility, mi-
gration, proliferation, production of extracellular matrix molecules, and
expression of ﬁbrogenic growth factors [8]. However, the actions of
these signaling molecules to bring about the physical and biochemical
modiﬁcations of myoﬁbroblast are less well understood and recent
progress will be discussed mainly on the basis of epigenetic regulation.
3. Mechanisms of altered DNA methylation in ﬁbrotic disease
DNA methylation is generally associated with repression of the
affected genes and is catalyzed by DNMTs [22]. Much work has been
devoted to describe the widespread alterations in global DNAmethyl-
ation patterns between ﬁbrosis and cancer or normal samples. Einat I.
Rabinovich et al. [23] have found that IPF lungs displayed an interme-
diate DNA methylation proﬁle, partly similar to lung cancer with 402
differentially methylated CpG islands overlapping. Global analysis of
DNA methylation in IPF samples implicated hypermethylation in
diseased tissue when compared with normal tissue samples [24], and
the same situation was also applied to a murine model of liver ﬁbrosis
[25]. Moreover, in support of the role for DNA methylation-related
modiﬁcations in IPF, Sanders et al. [26] quantiﬁed the expression of
DNMTs in IPF samples and indicated increased mRNA expression of de
novo enzymes (DNMT-3a, DNMT-3b) in disease as well as increased
DNMT-3a protein expression. Wibke Bechtel et al. [27] used a mouse
kidney model which was challenged with folic acid to gain insights
into the possible involvement of DNMTs in renal ﬁbrogenesis, and they
found that the expression of DNMT-1, but not of DNMT-3a and
DNMT-3b, was increased. As demonstrated above, various ﬁbroblast lit-
eratures have shown an abnormal expression of DNMTs in ﬁbrosis and
consequently displayed a hypermethylated proﬁle as promoting
myoﬁbroblast differentiation and, thus, disease progression.
Numerous studies have alluded to gene-speciﬁc hypermethylation
events as contributing to myoﬁbroblast differentiation. According to the
different or even reversal roles of these genes involved inﬁbrotic disease,
they can be divided into two categories; some of these genes have been
characterized as “ﬁbrosis suppressor genes”, which may function with
anti-ﬁbrosis roles, for example, Thy-1 [28], PTGER2 [29], RASAL1 [27],
PTEN [30], PPAR-γ [31–33], SOCS1/SOCS3 [34,35], SMAD4/7 [36,37],
FLI1 [37], and p14ARF [38]. Others are “ﬁbrosis genes”, which contribute
to ﬁbrotic disorders, such as SPP1 [25], ACTA [39], and DNAmethylation
related proteins—MeCP2 [33,40] (Table 1). Recent work has shown
that Thy-1 was down-regulated in ﬁbroblastic foci of IPF lungs through
promoter region hypermethylation, associated with a more proﬁbrotic
myoﬁbroblast phenotype. Itmay also be possible to restore Thy-1 expres-
sion upon exposure to DNA methylation inhibitor 5-azadeoxycytidine,
altering the proﬁbrotic phenotype of the cells and possibly the clinical
outcome in patients with IPF [28]. Furthermore, Steven et al. [29] have
found IPF patient-derived ﬁbroblasts and mice ﬁbrotic ﬁbroblasts that
both expressed low/no prostaglandin E receptor 2 (PTGER2). The loss
of PTGER2 expression was associated with hypermethylation of the
Table 1
Methylated genes in organ ﬁbrosis.
Organ Hypermethylated
gene
Hypomethylated
gene
Reference
Anti-ﬁbrosis genes Lung Thy-1 [28]
PTGER2 [29]
p14ARF [38]
Smad4 [36]
Kidney RASAL1 [27]
Liver RASAL1 [27]
PTEN [30]
SOCS1 [34]
SOCS3 [35]
PPARγ [31–33]
Skin FLI1 [37]
Smad7 [37]
Fibrosis genes Liver/lung ACTA [39,40]
Liver SPP1 [25]
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In addition, it also demonstrated that PGE2 resistance can be explained
by DNA hypermethylation of PTGER2 with subsequent silencing of
its gene product – E prostanoid 2 (EP2) – which is responsible for the
antiﬁbrotic actions [29]. More importantly, José Cisneros et al. [38] con-
ﬁrmed that P14ARF, normally acted as a tumor suppressor protein and
induced cell cycle arrest when upregulated, appeared to frequently un-
dergo CpG island hypermethylation which in turn led to a signiﬁcant
down-regulation of gene and protein expression in IPF ﬁbroblasts, thus
contributing to pulmonary ﬁbrosis. Hypermethylation of Smad4, a tran-
scription factor, which mediates TGFβ signaling, drives pulmonary ﬁbro-
sis and increases the risk of pulmonary carcinogenesis in IPF [36].
Similarly, epigenetic RASAL1 silencing due to hypermethylation of
the RASAL1 promoter regions caused myoﬁbroblast differentiation
and ultimately led to kidney ﬁbrosis in both the settings of pathological
kidney ﬁbrogenesis and physiological repair [27]. Moreover, Wibke
Bechtel et al. [27] further highlighted the importance of DNMT-1, for
that DNMT-1 knockdown with small interfering RNA could ameliorate
RASAL1 methylation in response to TGF-β1 and this helped to reverse
a hyperactive myoﬁbroblast phenotype. Fibrosis in the liver is similarly
correlated to RASAL1 hypermethylation, suggesting that transcription
is relevant for “organ ﬁbrosis” beyond the kidney [41,42]. Previous
evidence has shown thatﬁbroblast fromﬁbroblastic foci exhibited a dis-
tinct loss of PTEN, which has been related to the induction of a migrato-
ry phenotype and myoﬁbroblast differentiation [43]. Recently, in a
study aimed at discovering the therapy on epigenetically modiﬁed
PTEN in liver ﬁbrosis, the report has suggested that silencing DNMT-1
gene or treating activated HSC with DNA methylation inhibitor
5-aza-2′-deoxycytidine both decreased the PTEN gene promoter meth-
ylation and upregulated the PTEN gene expression, which may reverse
liver ﬁbrosis [30]. Takafumi Yoshida et al. [34] reported that SOCS1−/+
mice (with haploinsufﬁciency of the SOCS1 gene) may develop more
severe liver ﬁbroses than did SOCS1−/− mice (wild-type littermates)
in dimethylnitrosamine-induced murine liver ﬁbrosis models and the
severity of liver ﬁbrosis was strongly correlatedwith SOCS1 genemeth-
ylation, suggesting that SOCS1 methylation can be a useful diagnostic
indicator for liver ﬁbrosis risk and a new therapeutic target to protec-
tion against hepatic injury and ﬁbrosis. There were also similar reports
that in liver-speciﬁc SOCS3-deﬁcient mice, DNA methylation of the
SOCS3 gene in the liver resulted in hyperactivation of ﬁbroblasts and
promoted ConA- and chemical-induced liver ﬁbroses [35]. Another
relevant gene target subject to regulation by DNA methylation is PPARγ,
which is known as a repressor for α-SMA gene expression, whose
expression and interaction with MeCP2 result in inhibition of myo-
ﬁbroblast differentiation [31–33]. Apart from the ﬁbrosis-related organs
including lung, kidney and liver stated above. In scleroderma ﬁbroblasts,
ECM-inhibitory genes, such as Smad7 and FLI-1 are also hypermethylatedand consequently decreased, suggesting that DNA methylation could
cause derepression of ECM genes involved in ﬁbrosis [37].
While for the “ﬁbrosis genes”, it is supported by in-vitro experi-
ments that DNMTs-driven DNA hypermethylation of the ACTA gene
promoter abolishes its activity to promote hepatic myoﬁbroblast dif-
ferentiation and ﬁbrogenesis, namely that the methylated ACTA may
prevent or treat progressive ﬁbrotic disease [39]. Given that MeCP2 is
involved in mechanisms regulating gene sequences with methylated
DNA and the previous identiﬁcation of methylated DNA in the ACTA
gene, Biao Hu et al. [40] indicated that MeCP2 preferentially bound
the methylated ACTA gene promoter and enhanced ACTA gene ex-
pression. Further studies indicated that MeCP2-deﬁcient mice models
resulted in reduced ACTA gene expression and displayed lower pul-
monary collagen deposition and decreased myoﬁbroblast differentia-
tion compared with their wild-type littermates [40]. Thus the MeCP2
and DNA methylation may provide molecular mechanisms for per-
petuated ﬁbroblast activation and ﬁbrogenesis in pulmonary ﬁbrosis.
In addition, more recent studies by Yoko Komatsu et al. [25] revealed
that DNA hypomethylation of the SPP1 enhancer may precede the
up-regulation of SPP1 expression and induce the onset of CCl4-induced
early-stage liver ﬁbrosis.
In summary, the current reports imply that various gene-speciﬁc
methylation events may be responsible for changes in myoﬁbroblast
differentiation and of great importance that the DNMTs likely play
an essential part in regulating this process [44]. However the individual
roles of each of DNMTs (mainly DNMT-1, DNMT-3a, DNMT-3b) have
yet to be fully described in ﬁbrotic disease.
4. New advances of microRNAs in ﬁbrotic disease
MicroRNAs (miRNAs) are small noncoding RNAs that naturally exist
in mammalian cells and have roles in multiple physiological and patho-
logical functions, including growth, differentiation, proliferation and ap-
optosis [45]. In animals, single-stranded miRNAs bind, through partial
sequence homology, to the 3′ untranslated region (3′-UTR) of target
mRNAs and block translation or, less frequently, inducemRNAdegrada-
tion [11]. The past decade has seen the publication of many studies of
miRNAs relating to the regulation of myoﬁbroblast differentiation and
ﬁbrosis. Despite their various targets, their overall effect on ﬁbrotic
disease has begun to be identiﬁed. For example, miR-199a-5p, which
targets Caveolin-1 andmediates TGFβ-induced activated ﬁbroblast, en-
hances myoﬁbroblast differentiation in pulmonary ﬁbrosis and kidney
ﬁbrosis as well as CCl4-induced mouse models of liver ﬁbrosis [46].
Similarly, miR-145 by targeting KLF4, a known negative regulator of
α-SMA expression [47], miR-154 by targeting Smad3 [48] and miR-21,
by inhibiting the expression of Smad7 all have a positive effect on
myoﬁbroblast differentiation and contribute to pulmonary ﬁbrosis [49].
On the contrary, some miRNAs can be emerged as promising thera-
peutic targets for their negative effect in myoﬁbroblast differentiation,
for example, miR-31 which targets integrin-α and RhoA, inhibits the
proﬁbrotic activity of TGF-β1 and diminishes the ﬁbrogenic contractile,
and migratory activities of IPF ﬁbroblasts [50], miR-155 speciﬁcally re-
duces levels of angiotensin II type 1 receptor in rat aortic adventitial ﬁ-
broblasts, thereby inhibiting ERK1/2 phosphorylation and consequently
myoﬁbroblast differentiation and ﬁbrosis [51]. Furthermore, miR-29 is
negatively regulated by TGF-beta/Smad and has a therapeutic potential
for pulmonary ﬁbrosis by decreasing connective tissue growth factor
(CTGF) expression and Smad3 signaling [52].
Liver ﬁbrosis is a ﬁbroproliferative pathology of chronic liver dis-
ease and the transdifferentiation of quiescent HSC into an ‘activated’
myoﬁbroblastic phenotype is widely considered to be a pivotal event
in ﬁbrogenesis [8]. Some studies identiﬁed that some miRNAs were
upregulated during HSC transdifferentiation and HCV-induced liver
ﬁbrosis, such as miR-20a, miR-92a, and miR-214-5p [53,54]. Conversely,
other miRNAs, such as miR-122, miR-19b, miR-335, miR-150, miR-194,
miR-27 family, mir-15/16, miR-146a, and miR-181b are all decreased
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targeting various genes, thereby blunting HSC activation and ﬁbrogenesis
[55]. For example, miR-122 decreases collagen maturation and ECM pro-
duction via targeting P4HA1 expression in activated HSC [56]. And re-
cently, it has been demonstrated that miR-29 targeted proﬁbrogenic
genes including PDGF-C, IGF-I, and collagen types I and IV in activated he-
paticmyoﬁbroblasts, suggesting an antiﬁbrotic function ofmiR-29 in liver
ﬁbrosis [57,58], yet amazingly, for the other targets observed in lung can-
cer, miR-29 appears to enhance collagen gene transcription by targeting
DNMTs and consequently inhibiting DNA methylation [59]. Thus more
experiments are needed to unravel these apparently conﬂicting effects
of miR-29 on proﬁbrotic myoﬁbroblast phenotype in different situations.
With regard to renal ﬁbrosis,mir-29c, targets of COL2A1 and TPM1, is
down-regulated in renal interstitial ﬁbrosis in humans and rats and can
be restored by activation of HIF-α that attenuates ﬁbrosis [60]. For the
ﬁrst time, Kriegel AJ et al. [61] showed miR-382 targeted kallikrein 5
and contributed to the development of renal inner medullary interstitial
ﬁbrosis. Other ﬁbrosis-related microRNAs, including miR-192, miR-21,
and miR-324-3p, considered as novel targets for renal ﬁbrosis, result in
promotion of renal myoﬁbroblast differentiation [62,63]. In systemic
sclerosis (SSc), several miRNAs are involved in regulation of speciﬁc
genes in dermalﬁbroblasts, for example,miR-150mayplay an important
role in the pathogenesis of SSc via overexpression of integrin-β3 [64].
Following the comparison between normal and keloid-derived ﬁbro-
blast, mir-196, by targeting the expression of COL1A1 and COL3A1, indi-
cates its downregulation contributing to excessive collagen production
in keloid lesions [65]. All the publications concerned above have shown
a wide interest in the role of microRNAs in regulation of myoﬁbroblast
differentiation and ﬁbrotic disorders in different organs, especially in
the lung, liver, renal and scleroderma.
5. A dynamic interplay regulating DNMTs between miRNAs and
DNA methylation in ﬁbrotic disease
As previously stated, DNA methyltransferases (DNMTs) establish
and maintain DNA methylation which occurs normally in speciﬁc
genomic areas called CpG islands for their hypermethylated status
to prevent gene expression [15]. Accumulating studies about miRNAs
provide new and profound insights into the regulation of gene expres-
sion, in particularwith connected to DNAmethylation. To further explore
the underlyingmolecularmechanismsof this interaction,wehypothesize
that DNMTs may have an ability to link two repression mechanisms
together,whilemost investigations ofDNMTs focusedon thismutual reg-
ulation are frequently conﬁrmed in cancer research [66]. For example,
restoration of the down-regulatedmiR-29 has an ability to reverse the al-
tered DNAmethylation pattern and thus induce reexpression of silenced
tumor-suppressor genes (e.g.: FHIT andWWOX) in non-small lung can-
cer cells, since themiR-29 is proven to be a direct regulator of DNMT-3a
and DNMT-3b [67]. In addition, other miRNAs, including miR-148,
miR-152, miR-126 and miR-133 can also regulate DNMTs directly by
targeting the 3′-UTR of DNMT-1 in HBV-related hepatocellular carcino-
ma, systemic lupus erythematosus (SLE), cholangiocarcinoma cells and
diabetic cardiomyocytes, respectively [68–71]. Altogether, these ﬁnd-
ings indicate an important role for miRNAswhich target DNMTs during
oncogenesis and cancers. Whether the work in the cancer ﬁeld will ﬁnd
a similarity in clinical ﬁbrotic disease still needs to be seen further.
Although few literatures indicate the interplay between miRNAs
and DNA methylation, it directly focused on DNMTs in ﬁbrotic disease.
Recently, Dakhlallah D et al. [72] have conﬁrmed that there was amutu-
al regulation of miRNAs and DNAmethylation focused on DNMTs in the
pathogenesis of lung ﬁbrosis. The authors identiﬁed the differentially
expressedmiR-17–92 cluster and its role in regulating DNAmethylation
in IPF lung tissue. The level of miR-17–92 expression was reduced in
lung biopsies aswell as in lungﬁbroblasts frompatientswith IPF,where-
as DNMT-1 expression and methylation of the miR-17–92 promoter
were increased [72]. Additionally, several miRNAs from the miR-17–92cluster targeting DNMT-1 expression resulted in a negative feedback
loop andwhen treated ﬁbroblasts with 5-azaC can signiﬁcantly enhance
miR-17–92 cluster expression and attenuate pulmonary ﬁbrosis
through reducing DNMT-1 expression and ﬁbrotic gene. These results
demonstrated a DNMT-1-dependent regulation of miR-17–92 cluster
expression in the pathogenesis of lung ﬁbrosis [72].
MiR-133a is another new candidate targeted DNMTs involved
in the mutual regulation between miRNA and DNA methylation.
Christoph Roderburg et al. [73] showed that miR-133a was speciﬁcal-
ly downregulated during both hepatoﬁbrogenesis in vivo and upon
stimulation (TGF-β, but not TNF) of primary HSC in vitro, whereas
overexpression of miR-133a in HSC led to decreased expression of
collagens (e.g. Col1A1, Col5A3), thus contributing to reverse liver ﬁ-
brosis. Moreover, Scot J Matkovich et al. [74] have demonstrated
that miR-133a was downregulated in cardiac myoﬁbroblast differen-
tiation and protected against myocardial ﬁbrosis without affecting
the extent of hypertrophy. Additional study by Castoldi G et al. [75]
conﬁrmed that enforced expression of miR-133a could reverse myo-
cardial ﬁbrosis occurring in Ang II-dependent hypertension through
the downregulation of Col1A1 expression. These ﬁndings supported
a ﬁbrosis-suppressive role of miR-133a in the process of ﬁbrogenesis.
Interestingly, Vishalakshi Chavali et al. [76] suggested thatmiR-133awas
signiﬁcantly decreased and negatively regulated the DNMT (DNMT-1,
-3a and -3b) expression in diabetic cardiomyocytes. It was proved that
overexpression of miR-133a mitigated glucose mediated attenuation
of DNMT-1 and down-regulated DNMT-3a and DNMT-3b in diabetic
cardiomyocytes. In view of conservation in the miRNA evolution, future
studies about miR-133a on regulation of DNMT-1, -3a and -3b will
yield new insight into the pathogenesis ofmanydiseases, such as activat-
ed HSC-mediated liver ﬁbrosis (Fig. 1).
Besides the direct effect of miRNAs identiﬁed to bind to the 3′-UTR
of DNMTs, much work has been devoted to describe the mechanism
through which miRNAs may indirectly regulate DNMTs in ﬁbrotic dis-
ease. For example, miR-146a, which directly targets cyclooxygenases-2
(COX-2) by binding to the 3′-UTR of its transcript in COPD ﬁbroblasts,
is involved in regulation of COX2-derived prostaglandin E2 (PGE2)
[77]. Further research conﬁrms that reduced expression of miR-146a in
COPD ﬁbroblasts leads to reduced feedback degradation of COX-2
mRNA and consequent overproduction of PGE2, suggesting an indirect
and negative role of miR-146a in regulating PGE2 [77]. And this idea is
also conﬁrmed in bone marrow-derived mesenchymal stem cells
(BMSCs), for that miR-146a directly targets PGE2 synthase (PTGEs-2)
by using a luciferase reporter assay. And inhibition of miR-146a re-
stores synthesis of PGE2 and increases PGE2 expression [78]. Huang
SK et al. [79] showed that PGE2 could signal to increase global DNA
methylation and gene-speciﬁc DNA methylation in pulmonary ﬁbro-
blasts, mainly through up-regulating the expression and activity of
one speciﬁc isoform of DNA methyltransferase, DNMT-3a. In addition,
the increase in DNMT-3a expression is mediated by PGE2 signaling
via its E prostanoid 2 receptor and Sp1 (a transcription factor to in-
crease DNMT-3a expression), whereas silencing of DNMT-3a negates
the ability of PGE2 to increase DNMT activity. Taken together, these
ﬁndings may be particularly pertinent and imply that miR-146a may
be involved in regulating the abundance of DNMT-3a indirectly by reg-
ulating the expression of PGE2 in pulmonary ﬁbroblasts. Moreover, in
human Tenon's ﬁbroblasts, the decrease in Sp1 expression due to the
overexpression of miR-29b which acts as a suppressor of type I colla-
gen gene (COL1A1) via repressing the PI3K/Akt/Sp1 pathway in scar
formation, indicates another indirect regulation of miRNAs to DNMTs
[80] (Fig. 2).
In addition, it has been demonstrated that post-transcriptional
gene expression is controlled by multiple effects, including miRNAs
as well as Hu-antigen R (HuR). HuR, a protein that binds to target
mRNAs can enhance their stability and modulate their translation,
generally to promote their expression [81–83]. The ubiquitously
expressed HuR protein is previously shown to enhance the expression
miR-133a
COL1A1
Reverse myocardial fibrosis
COL1A1
COL5A3
Reverse hepatic fibrosis
A
B
C
DNMT-1,-3a,-3b
DNA methylation
Fig. 1. Interaction of miR-133a and DNMTs. (A) The expression ofmiR-133a is speciﬁcally
down-regulated in diabetic cardiomyocytes, whereas increasedmiR-133a signiﬁcantly re-
duces DNMT (DNMT-1, -3a and -3b) expression, thus regulating DNA methylation. The
expression of miR-133a is also decreased in Ang II-dependent hypertension-induced
myocardial ﬁbrosis (B) and TGF-β-induced hepatic ﬁbrosis(C), while overexpression of
miR-133a in each cell can lead to decreased expression of collagens (e.g. for hepatic ﬁbrosis:
Col1A1, Col5A3, for myocardial ﬁbrosis: Col1A1), thereby contributing to reverse ﬁbrosis.
DNA methylation
1874 X. Sun et al. / Cellular Signalling 25 (2013) 1870–1876of DNMT-3b post-transcriptionally by binding to its 3′-UTR [84] and ac-
cumulating evidences have indicated that lowered expression of HuR
was attributed to certain miRNAs, for example miR-519, miR-125a,
miR-16, miR-34a, and miR-7. The negative regulation of these miRNAs
to HuR consists in a direct connection with the HuR 3′-UTR and results
in a consequent translational repression. All the observations stated
above are mostly in cancer cell lines [85–89]. Currently, Woodhoo A
et al. [90] have demonstrated that HuR contributed to HSC activation
and its silencing signiﬁcantly reduced expression of HSC activation
markers (e.g. Col1A1, α-SMA). Additional research conﬁrms that HuR
is responsible for the stabilization of the TGFβ1 (as a major mediator
of liver ﬁbrogenesis) mRNA, which subsequently leads to increase of
TGFβ1 expression, thus induces ﬁbrogenic response in cardiacDNMT3a
B
COX-2
miR-146a
PGE2
PGE2 PGE2
PTGEs-2
PGE2
A
SP1
C
DNA methylation
COL1A1
miR-29b
Fibrosis
Fig. 2. The indirect interaction betweenmiR-146a/miR-29b and DNMT-3a. (A) MiR-146a
has homology with the 3′-UTR of COX-2 mRNA and suggests a mechanism whereby re-
duced expression of miR-146a in COPD ﬁbroblasts leads to reduced feedback degradation
of COX-2 mRNA and overexpression of COX-2 and consequent overproduction of PGE2.
(B) MiR-146a directly targets PGE2 synthase (PTGEs-2) post-transcriptionally by binding
to its 3′-UTR in bonemarrow-derivedmesenchymal stem cells (BMSCs). And inhibition of
miR-146a correlates with upregulation of PGE synthase-2 and increases PGE2 expression.
(C) PGE2 has been shown to target both DNMT-3a and SP1 (a transcription factor known
to increase DNMT-3a expression) to increase global DNA methylation and DNA methyla-
tion machinery in pulmonary ﬁbroblasts. Furthermore, the expression of miR-29b is
downregulated in TGFβ1-treated ﬁbroblast and increases a cadre of mRNAs that encode
proteins involved in ﬁbrosis, including Sp1 and Col1A1 by directly binding to their 3′-UTR.
And Sp1, which is also a transcriptional regulator of Col1A1 expression induced by TGF-β1,
contributes to the ﬁbrosis via overexpression of Col1A1 at the same time.ﬁbroblasts [91]. Given that the key mediator-HuR is involved in ﬁbrotic
disease, the hypothesis that negative regulation ofmiRNA toDNAmeth-
ylation which focused on DNMTs indirectly via the regulation of HuR
expression has a potential to become a new researchdirection in certain
disease. In light of the conservation in the miRNA evolution, the nega-
tive regulation of miRNAs to DNMT-3b in activated ﬁbroblasts needs
to be best studied in future to reveal its role in the pathogenesis of
liver and cardiac ﬁbrosis (Fig. 3).
6. Conclusion and prospective
As outlined in this review, there is now increasing evidence sug-
gested that the regulation of miRNAs to DNA methylation could regu-
late myoﬁbroblast differentiation and ﬁbrogenesis in ﬁbrotic disease.
But themechanismof themutual interaction as described in this review
is poorly understood. Recently, there have been several reports of the
epigenetic control of miRNA clusters, including miR-127, miR-124a,
miR-107, let-7a-3, and miR-1 in cancer cells [92–96]. These miRNAs,
which are embedded in a CpG island and keep epigenetically silenced
by promoter hypermethylation based on DNA methylation or chroma-
tin histone modiﬁcations can re-express when treated with epigenetic
drugs or applied to DNMT-null cell lines [66]. Moreover, epigenetic con-
trol of miRNAs may be miRNA-speciﬁc and epigenetic-effector-speciﬁc
(e.g. miR-1 is methylated mainly by DNMT-1, not by DNMT-3a or
DNMT-3b [96]). Although this regulatory role has been conﬁrmed
mostly in cancers, several aspects of this interaction still need to be
clariﬁed. For instance, it needs to investigate whether certain miRNAs
that are normally silenced by promoter hypermethylation can restore
in DNMT-null ﬁbroblasts, namely that the epigenetic regulation of
miRNAs is not only limited to cancer, but also plays a role in ﬁbrotic dis-
ease. Moreover, miRNAs directly targeting DNMTs induce an overall
global demethylation of cells, but how does this translate into a selec-
tive reexpression of hypermethylated anti-ﬁbrosis genes and not of
ﬁbrosis genes? Further investigations are needed in order to unravel
these questions and other concerns. Better understanding of this feed-
back loop between miRNAs and DNMTs involved in ﬁbrogenesis may
prove to be a big step towards understanding the molecular roots of
ﬁbrotic disease in future.miR-519
miR-125a
miR-16
miR-34a
miR-7
HuR
DNMT-3b
α-SMA/COL1A1 TGFβ-1
hepatic fibrosis myocardial fibrosis
A
B
C
Fig. 3. MiRNAs may negatively regulate DNMT-3b by HuR. (A) The levels of miR-519/
125a/16/34a/7 and HuR show inverse correlation in tissue pairs from certain cancer
patients: cancer tissues display high HuR and low miRNAs levels, while normal tissues
have high miRNAs and low HuR levels. (B) Furthermore, HuR has shown to stabilize
the DNMT-3bmRNA and increase DNMT-3b expression post-transcriptionally by binding
to its 3′-UTR during tumorigenesis. (C)While HuR is involved in contributing to ﬁbrotic
disease (e.g.: hepatic/myocardial ﬁbrosis) for that it is responsible for the stabilization of
the TGFβ1 and subsequently increases the expression of TGFβ1, as well as Col1A1 and
α-SMA.
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